Vedroprevir, or GS-9451, is a potent inhibitor of the HCV NS3 protease (Box 1). NS3 is a serine protease that cleaves the HCV polyprotein and helps generate the viral replication complex. Through binding NS3, vedroprevir halts the assembly of the viral replication complex, thus interfering with the assembly and release of viral particles. Vedroprevir is a potent inhibitor of NS3 protease with high selectivity against off-target proteases. It has rapid association kinetics and slow dissociation kinetics. Preclinical studies of vedroprevir showed high oral bioavailability in rats, dogs, and monkeys. Preclinical studies of vedroprevir demonstrated potent NS3 inhibition using laboratory strains as well as patient-derived NS3 protease gene isolates. In a phase I, randomized trial of vedroprevir monotherapy, doses of 200 and 400 mg/day yielded median maximal HCV RNA reductions of −3.2 log10 in genotype 1a patients and −3.5 log10 in genotype 1b patients. Significantly less activity was seen against genotype 2a HCV when compared to genotype 1. Vedroprevir was not listed on the Gilead Sciences pipeline in its 2014 annual report and appears to have been discontinued for the once-daily treatment of Hepatitis C.

The labeled 4-IODOPHENYLALANINE I-131 is used for proteomics research. It’s also can be used for the chemoselective modification of proteins.

FILOCICLOVIR, also known as cyclopropavir, is a guanosine nucleoside analog. It is an antiviral drug ready for phase II clinical trials for the treatment of cytomegalovirus infection.

BPR0L075 [6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole] is an anti-microtubule drug and is a promising anticancer compound with antimitotic activity. It has potential for management of various malignancies, particularly for patients with drug resistance. BPR0L075 inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin.

Deldeprevir (Neceprevir) is a direct-acting anti-HCV drug developed by Achillion. Deldeprevir acts by inhibition of the viral NS3/4A protease. In phase 1b clinical trial for the treatment of chronic HCV infection, the drug was safe and well-tolerated and produced more than a 3 log10 mean maximum reduction in plasma HCV RNA levels in all treated groups. Despite positive results, no development of the drug was reported by Achillion since 2014.